Whitehawk Therapeutics (WHWK) Interest Coverage Ratio (2010 - 2024)
Whitehawk Therapeutics (WHWK) posted quarterly Interest Coverage Ratio of 2.92 for Q1 2026, up 98.1% year-over-year from 1.47 in Q1 2025, and down 101.16% quarter-over-quarter from 251.38 in Q4 2025.
Powered by 
Analysis
Whitehawk Therapeutics (WHWK) Interest Coverage Ratio (2010 - 2024) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Interest Coverage Ratio for 17 consecutive years, with 2.92 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 98.1% year-over-year to 2.92; the TTM figure through Mar 2026 stood at 15.21 (up 87.31% YoY), while the FY2025 annual figure was 35.67, down 6346.0% from the prior year.
- Interest Coverage Ratio fell to 2.92 in Q1 2026 per WHWK's latest filing, from 251.38 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 251.38 in Q4 2025 and bottomed at 271.44 in Q4 2022.
- Historically, Interest Coverage Ratio has averaged 53.65 across 5 years, with a median of 46.25 in 2024.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio tumbled 1157.99% — and 2025, when it soared 691.68%.
- Whitehawk Therapeutics' Interest Coverage Ratio stood at 271.44 in 2022, then surged by 145.32% to 123.01 in 2023, then slumped by 134.54% to 42.49 in 2024, then jumped by 691.68% to 251.38 in 2025, then slumped by 101.16% to 2.92 in 2026.
- Business Quant data shows WHWK's Interest Coverage Ratio at 2.92 in Q1 2026, 251.38 in Q4 2025, and 36.26 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Whitehawk Therapeutics | 377.13 Mn | 377.13 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | -352.97 |
| Jun 30, 2024 | -268.69 |
| Mar 31, 2024 | -336.41 |
| Dec 31, 2023 | -310.77 |
| Sep 30, 2023 | -307.74 |
| Jun 30, 2023 | -336.98 |
| Mar 31, 2023 | -290.09 |
| Dec 31, 2022 | -271.44 |
| Sep 30, 2022 | -259.24 |
| Jun 30, 2022 | -316.55 |
| Mar 31, 2022 | -238.17 |
| Dec 31, 2021 | -279.74 |
| Sep 30, 2021 | -556.12 |
| Jun 30, 2021 | -17.07 |
| Mar 31, 2021 | -18.25 |
| Dec 31, 2020 | 36.54 |
| Sep 30, 2020 | -11.63 |
| Dec 31, 2016 | -1,285.65 |
| Sep 30, 2016 | -1,949.60 |
| Jun 30, 2016 | -1,721.37 |